Pharmaceutical Technology covers some of the highlights in blood cancer from ASCO 2026. Credit: inspiring.team / Shutterstock.com.
With the 2026 American Society of Clinical Oncology (ASCO) conference wrapping up, many are turning their attention to key readouts in the blood cancer space, with focus darting from more common indications like chronic lymphocytic leukaemia (CLL) and multiple myeloma to rare conditions like myelofibrosis.
As haematological malignancies generate a buzz at ASCO 2026, Pharmaceutical Technology highlights the key readouts from the disease area. Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Find out more
